肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展*

doi:10.3969/j.issn.1672-5069.2024.06.039

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (6): 953-956.doi: 10.3969/j.issn.1672-5069.2024.06.039

肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展^*

王玲玲, 姚敏综述, 姚登福审校

226001 南通市南通大学医学院免疫学系(王玲玲,姚敏);附属医院临床医学研究中心(姚登福)

收稿日期:2023-10-19 出版日期:2024-11-10 发布日期:2024-11-07
通讯作者: 姚登福,E-mail:yaodf@ahnmc.com
作者简介:王玲玲,女,硕士研究生。研究方向:炎症与免疫。E-mail: ling456856@163.com
基金资助:
^*国家自然科学基金面上项目(编号:81673241);南通市传染病防治联盟科研项目(编号:202308001)

Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma

Wang Lingling, Yao Min, Yao Dengfu

Department of Immunology, Research Center of Clinical Medicine, Affiliated Hospital, Nantong University, Nantong 226001, Jiangsu Province, China

Received:2023-10-19 Online:2024-11-10 Published:2024-11-07

摘要/Abstract

摘要： 肝细胞癌(HCC)发生机制尚未完全阐明,肝细胞恶性转化的监测极其重要。新近发现在HCC进展过程中,人类最大的锌指蛋白转录因子家族的Krüppel样因子(KLFs)发挥重要的促进或抑制作用。基础和临床研究显示部分KLFs有望成为诊断和预测HCC预后的分子标志物,并有望成为基因治疗的分子靶标。本文综述了肝癌相关KLFs的组织分布,表达特征及其临床应用价值。

关键词: 肝细胞癌, Krüppel样因子, 诊断, 分子靶标

Abstract: The mechanisms of hepatocarcinogenesis have not been fully elucidated. Krüppel-like factors (KLFs), the largest family of zinc finger protein (ZFP) transcription factors in humans, have recently been found to play a promoting or inhibiting role in hepatocellular carcinoma (HCC) progression. Basic and clinical studies have shown that part of KLFs might be used as molecular markers for diagnosis and for predicting prognosis of patients with HCC. It is also possible as a molecular targets for gene therapy. This article reviews the tissue distribution, expressing features and clinical application of HCC-related KLFs.

Key words: Hepatocellular carcinoma, Krüppel-like factors, Diagnosis, Molecular target

王玲玲, 姚敏, 姚登福. 肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 953-956.

Wang Lingling, Yao Min, Yao Dengfu. Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2024, 27(6): 953-956.

参考文献

[1] McGlynn KA, Petrick JL, El-Serag HB.Epidemiology of hepatocellular carcinoma. Hepatology, 2021, 73(S1):4-13.
[2] Shah PA, Patil R, Harrison SA.NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology, 2023, 77(1):323-338.
[3] Jen J, Wang YC.Zinc finger proteins in cancer progression. J Biomed Sci, 2016, 23(1):53.
[4] Liu Y, Ma D, Ji C.Zinc fingers and homeoboxes family in human diseases. Cancer Gene Ther, 2015, 22(5):223-226.
[5] Caria CA, Faà V, Ristaldi MS. Krüppel-like factor 1: A pivotal gene regulator in erythropoiesis. Cells, 2022, 11(19):3069.
[6] Taghehchian N, Maharati A, Akhlaghipour I, et al.PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression. Cancer Cell Int, 2023, 23(1):233.
[7] Tian B, Zhou L, Wang J,et al. miR-660-5p-loaded M2 macrophages-derived exosomes augment hepatocellular carcinoma development through regulating KLF3. Int Immunopharmacol, 2021, 101(Pt B):108157.
[8] Jia X, Li L, Wang F,et al. DUB3/KLF4 combats tumor growth and chemoresistance in hepatocellular carcinoma. Cell Death Discov, 2022, 8(1):166.
[9] An T, Dong T, Zhou H,et al. The transcription factor Krüppel-like factor 5 promotes cell growth and metastasis via activating PI3K/AKT/Snail signaling in hepatocellular carcinoma. Biochem Biophys Res Commun, 2019, 508(1):159-168.
[10] Vetter D, Cohen-Naftaly M, Villanueva A,et al. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology, 2012, 56(4):1361-1370.
[11] Guo Y, Chai B, Jia J,et al. KLF7/VPS35 axis contributes to hepatocellular carcinoma progression through CCDC85C-activated β-catenin pathway. Cell Biosci, 2021, 11(1):73.
[12] Wang MD, Xing H, Li C,et al. A novel role of Krüppel-like factor 8 as an apoptosis repressor in hepatocellular carcinoma. Cancer Cell Int, 2020, 20:422.
[13] Sun J, Wang B, Liu Y,et al. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Lett, 2014,355(1):25-33.
[14] Li D, Lu L, Liu M,et al. Inhibition of long noncoding RNA cancer susceptibility candidate 7 attenuates hepatocellular carcinoma development by targeting micro RNA-30a-5p. Bioengineered, 2022,13(4):11296-11308.
[15] Hujie G, Zhou SH, Zhang H,et al. MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma. Cancer Cell Int, 2018, 18:10.
[16] Wang J, Pu J, Zhang Y,et al. DANCR contributed to hepatocellular carcinoma malignancy via sponging miR-216a-5p and modulating KLF12. J Cell Physiol, 2019, 234(6):9408-9416.
[17] Chen CC, Xie XM, Zhao XK,et al. Krüppel-like factor 13 promotes HCC progression by transcriptional regulation of HMGCS1-mediated cholesterol synthesis. J Clin Transl Hepatol, 2022, 10(6):1125-1137.
[18] Zhou H, Chen J, Fan M,et al. KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive elementbinding protein 2.J Exp Clin Cancer Res, 2023, 42(1):5.
[19] Jiang Z, Elsarrag SZ, Duan Q,et al. KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. Sci Adv, 2022, 8(10):eabj2917.
[20] Sun N, Shen C, Zhang L,et al. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.Gut, 2021, 70(11): 2183-2195.
[21] Liu FY, Deng YL, Li Y,et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol, 2013, 30(1):425.
[22] Pei J, Grishin NV.C2H2 zinc finger proteins of the SP/KLF, Wilms tumor, EGR, Huckebein, and Klumpfuss families in metazoans and beyond.Gene, 2015, 573(1): 91-99.
[23] Yerra VG, Drosatos K.Specificity proteins (SP) and Krüppel-like factors (KLF) in liver physiology and pathology.Int J Mol Sci, 2023, 24(5):4682.
[24] Fu M, Blackshear PJ.RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins. Nat Rev Immunol, 2017, 17(2):130-143.
[25] Zeng L, Zhu Y, Moreno CS, et al.New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy. Semin Cancer Biol, 2023, 90(1):29-44.
[26] Hu K, Zheng QK, Ma RJ, et al.Kruppel-like factor 6 splice variant 1: An oncogenic transcription factor involved in the progression of multiple malignant tumors. Front Cell Dev Biol, 2021, 9:661731.
[27] Cheng S, Zhang X, Xu Y,et al. Krüppel-like factor 8 regulates VEGFA expression and angiogenesis in hepatocellular carcinoma. Sci Rep, 2018, 8(1):17415.
[28] Li Y, Yu S, Li L, et al.KLF4-mediated upregulation of CD9 and CD81 suppresses hepatocellular carcinoma development via JNK signaling. Cell Death Dis, 2020, 11(4):299.
[29] Kong LM, Yao L, Lu N,et al. Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. Oncotarget, 2016, 7(19):27975-27987.
[30] Memon A, Lee WK. KLF10 as a tumor suppressor gene and its TGF-beta signaling. Cancers (Basel), 2018, 10(6):161.
[31] Ali A, Zhang P, Liangfang Y, et al. KLF17 empowers TGF-beta/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression. Cell Death Dis, 2015, 6(3):e1681.
[32] 赛文莉, 王理, 孙建英, 等. 锌指蛋白转录因子Krüppel样因子5异常表达对肝细胞癌诊断及预后的价值. 中华肝脏病杂志, 2021,29(8):781-787.
[33] Wu W, Liu S, Liang Y, et al.MiR-7 inhibits progression of hepatocarcinoma by targeting KLF-4 and promises a novel diagnostic biomarker. Cancer Cell Int, 2017, 17:31.
[34] Xue M, Zhou C, Zheng Y, et al.The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. Aging (Albany NY), 2020, 12(15):15566-15580.
[35] Zhang Y, Yao C, Ju Z, et al.Krüppel-like factors in tumors: Key regulators and therapeutic avenues. Front Oncol, 2023, 13:1080720.

肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展^*

Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[2]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[3]	朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.
[4]	周隽, 张忠新, 徐海燕. 可视化瞬时弹性成像与声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 832-835.
[5]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[6]	唐敏, 曾理, 杨鑫荣. FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 887-890.
[7]	陈思艳, 郭道宁, 邹晓攀, 漆家高. 彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 899-902.
[8]	曾旺, 蔡晓曼, 葛尚. 肝内胆管细胞癌与肝细胞癌病灶MRI增强扫描表现差异分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 907-910.
[9]	丹巴玉珍, 程盼. 增强MRI检查诊断HCC价值研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 911-914.
[10]	杨佳欣, 杨紫郡, 陈卫. 双源CT双能量TNC技术图像质量与诊断肝细胞癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 915-918.
[11]	邓娜, 郑玉凤, 刘旭红, 韩晓兵, 丁碧娇, 曾纬阳, 刘娜红, 黄莹, 陈梅桂. CT动态增强扫描诊断原发性肝癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 919-922.
[12]	马紫瑶, 王超, 赵珏, 冯赟, 张铭, 梁凯轶. MRI诊断不典型肝脓肿临床应用价值分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 931-934.
[13]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[14]	杨逸铭, 李晓环, 刘玉品, 欧金龙, 黎胜, 石美凤, 汪印强. FibroScan、MRI-PDFF和FAST评分识别高危非酒精性脂肪性肝炎患者临床应用研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 701-704.
[15]	谢爱萍, 赵景, 蒋祁明, 何秀波. 超声声衰减系数与受控衰减参数联合肝脏硬度检测诊断NAFLD患者NASH发生效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 705-708.